Back to search results

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

IsraelRecruitingPHASE3

Conditions

Systemic Lupus Erythematosus

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Pinnacle Research Group Llc, Anniston, Alabama, United States

    Contact: Study coordinator (Ruby Fields) · rfields@pinnacletrials.com · 256-236-0055
    Contact: Principal Investigator (Vishala L Chindalore)

  • Providence Medical Center, Burbank, California, United States

    Contact: Study coordinator (Sandra Figueroa) · Sandra.Figueroa@providence.org · 818-869-7067
    Contact: Principal Investigator (Sue Chung)

  • Advanced Medical Research, La Palma, California, United States

    Contact: Study coordinator (Alejandro Merazo) · amerazo@advmedresearch.com · 714-752-6587
    Contact: Principal Investigator (Gerald Ho)

  • Millennium Clinical Trials, Westlake Village, California, United States

  • University of Colorado Denver, Aurora, Colorado, United States

    Contact: Study coordinator (Chong Pedrick) · chong.pedrick@cuanschutz.edu
    Contact: Principal Investigator (Christopher Striebich)

  • Clinical Res Of W Florida, Clearwater, Florida, United States

    Contact: Study coordinator (Jessica Mayfield) · JMayfield@crwf.com · 727-466-0078
    Contact: Principal Investigator (Robert Levin)

  • GNP Research, Cooper City, Florida, United States

    Contact: Study coordinator (Melissa Pierce) · melissa@gnpresearch.com · 754-248-3589
    Contact: Principal Investigator (Mark Jaffe)

  • IRIS Research and Development, Plantation, Florida, United States

    Contact: Study coordinator (Jhon Galindo) · jgalindo@irisrheumatology.com · 954-476-2338
    Contact: Principal Investigator (Guillermo Valenzuela)

  • Clinical Research of West Florida Inc, Tampa, Florida, United States

    Contact: Study coordinator (Abby Carlson) · ACarlson@crwf.com · 813-870-1292
    Contact: Principal Investigator (John Carter)

  • Parris and Associates Rheumatology, Lawrenceville, Georgia, United States

    Contact: Study coordinator (Mannai Coutermarsh) · m.coutermarsh@parrisandassociates.net · +17709621616#8334
    Contact: Principal Investigator (Glenn Parris)

  • Robert A Hozman MD SC, Skokie, Illinois, United States

    Contact: Study coordinator (Patrycja Kalwajtys) · pkalwajtys@cisresearch.com · 847-727-2743
    Contact: Principal Investigator (Robert Hozman)

  • Willow Rheumatology Wellness, Willowbrook, Illinois, United States

    Contact: Study coordinator (Lubna Ali) · lali@willowrheum.com
    Contact: Principal Investigator (Angela R Crowley)

  • Accurate Clinical Research, Lake Charles, Louisiana, United States

    Contact: Study coordinator (Machell Broussard) · mbroussard@accurateclinicalresearch.com
    Contact: Principal Investigator (Enrique Mendez)

  • University Of Maryland, Baltimore, Maryland, United States

  • Henry Ford Health, Detroit, Michigan, United States

    Contact: Study coordinator (Jenna Hudy) · jhudy1@hfhs.org · 313-916-1984
    Contact: Principal Investigator (Alireza Meysami)

  • Ahmed Arif Medical Research Center, Grand Blanc, Michigan, United States

    Contact: Study coordinator (Iman Abdelrahman) · iman@aamrc.net · 810-953-8700
    Contact: Principal Investigator (Ali Karrar)

  • Paramount Med Rsrch and Consult LLC, Middleburg Heights, Ohio, United States

    Contact: Study coordinator (Denine Ryan) · deniner64@gmail.com · 440-891-9395
    Contact: Principal Investigator (Isam Diab)

  • West Tennessee Research Institute, Jackson, Tennessee, United States

    Contact: Study coordinator (Abbie Hinton) · ahinton@arthritisclinic.org · 731-633-0119
    Contact: Principal Investigator (Jacob A Aelion)

  • Shelby Research LLC, Memphis, Tennessee, United States

    Contact: Study coordinator (Suvarna Konangula) · shelbyres1999@outlook.com · 901-681-9670
    Contact: Principal Investigator (Ramesh C Gupta)

  • Novel Research LLC, Bellaire, Texas, United States

  • Accurate Clinical Research, League City, Texas, United States

    Contact: Study coordinator (Mariela Martinez) · mmartinez@accurateclinicalresearch.com
    Contact: Principal Investigator (Sabeen Najam)

  • Epic Medical Research, Red Oak, Texas, United States

    Contact: Study coordinator (Harshini Potluri) · hpotluri@epicmedresearch.com · 469-206-2642
    Contact: Principal Investigator (Sunny Patel)

  • Novartis Investigative Site, La Plata, Buenos Aires, Argentina

  • Novartis Investigative Site, Quilmes, Buenos Aires, Argentina

  • Novartis Investigative Site, San Miguel, Buenos Aires, Argentina

  • Novartis Investigative Site, San Miguel, Tucumán Province, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, San Miguel de Tucumán, Argentina

  • Novartis Investigative Site, Maroochydore, Queensland, Australia

  • Novartis Investigative Site, Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil

  • Novartis Investigative Site, Niterói, Rio de Janeiro, Brazil

  • Novartis Investigative Site, Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site, Barretos, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Salvador, Brazil

  • Novartis Investigative Site, Plovdiv, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Vancouver, British Columbia, Canada

  • Novartis Investigative Site, Rimouski, Quebec, Canada

  • Novartis Investigative Site, Valdivia, Los Ríos Region, Chile

  • Novartis Investigative Site, Santiago, RM, Chile

  • Novartis Investigative Site, Santiago, Santiago Metropolitan, Chile

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Shantou, Guangdong, China

  • Novartis Investigative Site, Nanjing, Jiangsu, China

  • Novartis Investigative Site, Suzhou, Jiangsu, China

  • Novartis Investigative Site, Nanchang, Jiangxi, China

  • Novartis Investigative Site, Pingxiang, Jiangxi, China

  • Novartis Investigative Site, Changchun, Jilin, China

  • Novartis Investigative Site, Linyi, Shandong, China

  • Novartis Investigative Site, Chengdu, Sichuan, China

  • Novartis Investigative Site, Ürümqi, Xinjiang, China

  • Novartis Investigative Site, Ningbo, Zhejiang, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Xinxiang, China

  • Novartis Investigative Site, Medellín, Antioquia, Colombia

  • Novartis Investigative Site, Barranquilla, Atlántico, Colombia

  • Novartis Investigative Site, Chía, Cundinamarca, Colombia

  • Novartis Investigative Site, Bucaramanga, Santander Department, Colombia

  • Novartis Investigative Site, Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site, Bogotá, Colombia

  • Novartis Investigative Site, Brno, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Uherské Hradiště, Czechia

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site, Leipzig, Saxony, Germany

  • Novartis Investigative Site, Guatemala City, Guatemala

  • Novartis Investigative Site, Székesfehérvár, Fejér, Hungary

  • Novartis Investigative Site, Gyula, Hungary

  • Novartis Investigative Site, Zalaegerszeg, Hungary

  • Novartis Investigative Site, Ahmedabad, Gujarat, India

  • Novartis Investigative Site, Ahmedabad, Gujarat, India

  • Novartis Investigative Site, Kozhikode, Kerala, India

  • Novartis Investigative Site, Kolhāpur, Maharashtra, India

  • Novartis Investigative Site, Nagpur, Maharashtra, India

  • Novartis Investigative Site, Nashik, Maharashtra, India

  • Novartis Investigative Site, Pune, Maharashtra, India

  • Novartis Investigative Site, New Delhi, India

  • Novartis Investigative Site, New Delhi, India

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Ramat Gan, Israel

  • Novartis Investigative Site, Pisa, PI, Italy

  • Novartis Investigative Site, Torino, TO, Italy

  • Novartis Investigative Site, Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site, Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Yokohama, Kanagawa, Japan

  • Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan

  • Novartis Investigative Site, Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site, Fuchū, Tokyo, Japan

  • Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan

  • Novartis Investigative Site, Ipoh, Perak, Malaysia

  • Novartis Investigative Site, León, Guanajuato, Mexico

  • Novartis Investigative Site, Guadalajara, Jalisco, Mexico

  • Novartis Investigative Site, Mexico City, Mexico City, Mexico

  • Novartis Investigative Site, Morelia, Michoacán, Mexico

  • Novartis Investigative Site, Mérida, Yucatán, Mexico

  • Novartis Investigative Site, México, Mexico

  • Novartis Investigative Site, Wroclaw, Lower Silesian Voivodeship, Poland

  • Novartis Investigative Site, Bydgoszcz, Poland

  • Novartis Investigative Site, Bydgoszcz, Poland

  • Novartis Investigative Site, Bytom, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Braga, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Cluj-Napoca, Cluj, Romania

  • Novartis Investigative Site, Brasov, Romania

  • Novartis Investigative Site, Bucharest, Romania

  • Novartis Investigative Site, Košice, Slovakia

  • Novartis Investigative Site, Pretoria, Gauteng, South Africa

  • Novartis Investigative Site, Cape Town, Western Cape, South Africa

  • Novartis Investigative Site, Cape Town, Western Cape, South Africa

  • Novartis Investigative Site, Somerset West, Western Cape, South Africa

  • Novartis Investigative Site, Umhlanga, South Africa

  • Novartis Investigative Site, Gwangju, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site, Badalona, Barcelona, Spain

  • Novartis Investigative Site, Santander, Cantabria, Spain

  • Novartis Investigative Site, Barcelona, Catalonia, Spain

  • Novartis Investigative Site, San Sebastian Reyes, Madrid, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, Taichung, Taiwan

  • Novartis Investigative Site, Taichung, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taoyuan, Taiwan

  • Novartis Investigative Site, Bangkok, Thailand

  • Novartis Investigative Site, Bangkok, Thailand

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)